United Drug plc will seek shareholder approval for the share repurchase program at its Annual General Meeting to be held on February 12, 2013. Under the program, the company will repurchase up 24,728,369 shares, representing 10% of its issued share capital. The minimum price which may be paid per ordinary share will be the nominal value of the share.

The maximum price (excluding expenses) which may be paid for any share shall be the higher of either 5% above the average of the closing prices of a Relevant Share taken from the Official List of the London Stock Exchange for the five business days prior to the day the purchase is made and the amount stipulated by Article 5(1) of the Market Abuse (Buyback and Stabilisation) Regulation (EC) No. 2273/2003 of December 22, 2003 (being the value of a share calculated on the basis of the higher of the price quoted for either the last independent trade of; and the highest current independent bid for any number of shares on the trading venue where the purchase pursuant to the authority conferred by the resolution will be carried out. This authority will provide flexibility in the management of the company's capital and will be exercised only if the Directors consider it to be in the best interests of the company and its shareholders as a whole.

The program will expire at the conclusion of the next Annual General Meeting or on May 11, 2014, whichever is earlier, unless previously renewed, varied or revoked by the company in a general meeting.